Ergomed Plc (LON:ERGO), the drug development and pharma services company, has brought forward the reporting date for top-line results for its phase-IIb trial of a potential blockbuster blood thickening agent.
Having reached the recruitment mid-point for coagulant PeproStat, it expects to deliver the first data from the study by the fourth-quarter of this year, rather than in the first three months of 2018.
WATCH: Interest in Ergomed's blood thickener 'significant', says CEO Miroslav Reljanovic
"The accelerated recruitment of this phase-IIb trial demonstrates not only strong physician interest in this innovative haemostat but also Ergomed's ability as a specialist drug developer to efficiently recruit patients and conduct studies faster than industry standards,” said chief executive, Dr Miroslav Reljanovic.
Big market
The company reckons the thickening agent, which is used to staunch bleeding during surgery, has the potential to tap into a market worth US$2.1bn.
PeproStat, based on a synthetic peptide which eliminates the risk of exposure to blood-derived materials, is more stable than existing products and has a fast mode of action.
“With these advantages Ergomed expects the product will gain significant market share,” the company said.